Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 49 entries
Sorted by: Best Match Show Resources per page
Clinical experience with nonstandard doses ofinterferon alfa-2b and ribavirin in the treatment of chronic hepatitis C infection: A retrospective analysis.

Current therapeutic research, clinical and experimental

Hare CB, Loveland JJ, Chu A, Morris JA, Gotz V, Klaskala W.
PMID: 24790244
Curr Ther Res Clin Exp. 2005 Sep;66(5):433-50. doi: 10.1016/j.curtheres.2005.10.005.

BACKGROUND: Hepatitis C virus (HCV) infection is the most common blood-borne virus in the United States. Several mono- and combination therapies have been approved by the US Food and Drug Administration for the treatment of HCV, but their routes...

Cite
Hare CB, Loveland JJ, Chu A, et al. Clinical experience with nonstandard doses ofinterferon alfa-2b and ribavirin in the treatment of chronic hepatitis C infection: A retrospective analysis. Curr Ther Res Clin Exp. 2005;66(5):433-50doi: 10.1016/j.curtheres.2005.10.005.
Hare, C. B., Loveland, J. J., Chu, A., Morris, J. A., Gotz, V., & Klaskala, W. (2005). Clinical experience with nonstandard doses ofinterferon alfa-2b and ribavirin in the treatment of chronic hepatitis C infection: A retrospective analysis. Current therapeutic research, clinical and experimental, 66(5), 433-50. https://doi.org/10.1016/j.curtheres.2005.10.005
Hare, C Bradley, et al. "Clinical experience with nonstandard doses ofinterferon alfa-2b and ribavirin in the treatment of chronic hepatitis C infection: A retrospective analysis." Current therapeutic research, clinical and experimental vol. 66,5 (2005): 433-50. doi: https://doi.org/10.1016/j.curtheres.2005.10.005
Hare CB, Loveland JJ, Chu A, Morris JA, Gotz V, Klaskala W. Clinical experience with nonstandard doses ofinterferon alfa-2b and ribavirin in the treatment of chronic hepatitis C infection: A retrospective analysis. Curr Ther Res Clin Exp. 2005 Sep;66(5):433-50. doi: 10.1016/j.curtheres.2005.10.005. PMID: 24790244; PMCID: PMC4003805.
Copy Download .nbib Format: NLM
Combination immunotherapy for high-risk resected and metastatic melanoma patients.

The Ochsner journal

Riker AI, Rossi GR, Masih P, Alsfeld LC, Denham F, Tennant L, Ramsey WJ, Vahanian NN, Link CJ.
PMID: 24940124
Ochsner J. 2014;14(2):164-74.

BACKGROUND: Patients with advanced melanoma have a poor outcome. We hypothesize that combination immunotherapy can synergistically activate host immunity to generate an effective treatment for patients with high-risk, resected stage 3, recurrent, refractory, or stage 4 melanoma.METHODS: We conducted...

Cite
Riker AI, Rossi GR, Masih P, et al. Combination immunotherapy for high-risk resected and metastatic melanoma patients. Ochsner J. 2014;14(2):164-74
Riker, A. I., Rossi, G. R., Masih, P., Alsfeld, L. C., Denham, F., Tennant, L., Ramsey, W. J., Vahanian, N. N., & Link, C. J. (2014). Combination immunotherapy for high-risk resected and metastatic melanoma patients. The Ochsner journal, 14(2), 164-74.
Riker, Adam I, et al. "Combination immunotherapy for high-risk resected and metastatic melanoma patients." The Ochsner journal vol. 14,2 (2014): 164-74.
Riker AI, Rossi GR, Masih P, Alsfeld LC, Denham F, Tennant L, Ramsey WJ, Vahanian NN, Link CJ. Combination immunotherapy for high-risk resected and metastatic melanoma patients. Ochsner J. 2014;14(2):164-74. PMID: 24940124; PMCID: PMC4052581.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 12616965
Methods Find Exp Clin Pharmacol. 2002 Dec;24(10):703-29.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002;24(10):703-29
Bayés, M., Rabasseda, X., & Prous, J. R. (2002). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 24(10), 703-29.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 24,10 (2002): 703-29.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002 Dec;24(10):703-29. PMID: 12616965.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 15148527
Methods Find Exp Clin Pharmacol. 2004 Apr;26(3):211-44.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity(R), the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004;26(3):211-44
Bayés, M., Rabasseda, X., & Prous, J. R. (2004). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 26(3), 211-44.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 26,3 (2004): 211-44.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Apr;26(3):211-44. PMID: 15148527.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Tomillero A, Moral MA.
PMID: 18985183
Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88.

Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008;30(7):543-88
Tomillero, A., & Moral, M. A. (2008). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 30(7), 543-88.
Tomillero, A, and Moral, M A. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 30,7 (2008): 543-88.
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88. PMID: 18985183.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 16082422
Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):331-72.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005;27(5):331-72
Bayés, M., Rabasseda, X., & Prous, J. R. (2005). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 27(5), 331-72.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 27,5 (2005): 331-72.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):331-72. PMID: 16082422.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayes M, Rabasseda X, Prous JR.
PMID: 16845450
Methods Find Exp Clin Pharmacol. 2006 Jun;28(5):323-43.

Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006;28(5):323-43
Bayes, M., Rabasseda, X., & Prous, J. R. (2006). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 28(5), 323-43.
Bayes, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 28,5 (2006): 323-43.
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Jun;28(5):323-43. PMID: 16845450.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Tomillero A, Moral MA.
PMID: 20508873
Methods Find Exp Clin Pharmacol. 2010 May;32(4):247-88. doi: 10.1358/mf.2010.32.4.1507200.

O(6)-Benzylguanine; (-)-Gossypol; Abatacept, AC-2592, Adalimumab, AIDSVAX gp120 B/E, Alemtuzumab, Aliskiren fumarate, ALVAC E120TMG, Ambrisentan, Amlodipine, Anakinra, Aripiprazole, Armodafinil, Atomoxetine hydrochloride, Avotermin; Bevacizumab, BIBW-2992, Bortezomib, Bosentan, Botulinum toxin type B; Canakinumab, CAT-354, Ciclesonide, CMV gB vaccine, Corifollitropin alfa, Daptomycin, Darbepoetin...

Cite
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010;32(4):247-88doi: 10.1358/mf.2010.32.4.1507200.
Tomillero, A., & Moral, M. A. (2010). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 32(4), 247-88. https://doi.org/10.1358/mf.2010.32.4.1507200
Tomillero, A, and Moral, M A. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 32,4 (2010): 247-88. doi: https://doi.org/10.1358/mf.2010.32.4.1507200
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 May;32(4):247-88. doi: 10.1358/mf.2010.32.4.1507200. PMID: 20508873.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayes M, Rabasseda X, Prous JR.
PMID: 16082427
Methods Find Exp Clin Pharmacol. 2005 May;27(4):265-84.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005;27(4):265-84
Bayes, M., Rabasseda, X., & Prous, J. R. (2005). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 27(4), 265-84.
Bayes, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 27,4 (2005): 265-84.
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 May;27(4):265-84. PMID: 16082427.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayes M, Rabasseda X, Prous JR.
PMID: 18040531
Methods Find Exp Clin Pharmacol. 2007 Oct;29(8):547-83.

(-)-Epigallocatechin gallate, [188Re]-P2045, 12B75, 89-12; Abacavir sulfate/lamivudine, Abatacept, Abiraterone acetate, ABT-869, Adalimumab, Ad-rh Endostatin, AI-700, Alemtuzumab, Alvimopan hydrate, Amrubicin hydrochloride, AP-12009, Apomab 7.3, Arformoterol tartrate, Aripiprazole, AS-1404, Azacitidine, AZD-0530; Bevacizumab, BHT-3009, Biapenem, Bortezomib, Bosentan, Bremelanotide; CA9-SCAN, Calcitonin gene-related peptide,...

Cite
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007;29(8):547-83
Bayes, M., Rabasseda, X., & Prous, J. R. (2007). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 29(8), 547-83.
Bayes, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 29,8 (2007): 547-83.
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Oct;29(8):547-83. PMID: 18040531.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayes M, Rabasseda X, Prous JR.
PMID: 15319815
Methods Find Exp Clin Pharmacol. 2004 Jun;26(5):357-91.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity, the drug...

Cite
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004;26(5):357-91
Bayes, M., Rabasseda, X., & Prous, J. R. (2004). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 26(5), 357-91.
Bayes, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 26,5 (2004): 357-91.
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Jun;26(5):357-91. PMID: 15319815.
Copy Download .nbib Format: NLM
Predicting the outcomes of combination therapy in patients with chronic hepatitis C using artificial neural network.

Hepatitis monthly

Sargolzaee Aval F, Behnaz N, Raoufy MR, Alavian SM.
PMID: 24976838
Hepat Mon. 2014 Jun 01;14(6):e17028. doi: 10.5812/hepatmon.17028. eCollection 2014 Jun.

BACKGROUND: Treatment with Peginterferon Alpha-2b plus Ribavirin is the current standard therapy for chronic hepatitis C (CHC). However, many host related and viral parameters are associated with different outcomes of combination therapy.OBJECTIVES: The aim of this study was to...

Cite
Sargolzaee Aval F, Behnaz N, Raoufy MR, et al. Predicting the outcomes of combination therapy in patients with chronic hepatitis C using artificial neural network. Hepat Mon. 2014;14(6):e17028doi: 10.5812/hepatmon.17028.
Sargolzaee Aval, F., Behnaz, N., Raoufy, M. R., & Alavian, S. M. (2014). Predicting the outcomes of combination therapy in patients with chronic hepatitis C using artificial neural network. Hepatitis monthly, 14(6), e17028. https://doi.org/10.5812/hepatmon.17028
Sargolzaee Aval, Forough, et al. "Predicting the outcomes of combination therapy in patients with chronic hepatitis C using artificial neural network." Hepatitis monthly vol. 14,6 (2014): e17028. doi: https://doi.org/10.5812/hepatmon.17028
Sargolzaee Aval F, Behnaz N, Raoufy MR, Alavian SM. Predicting the outcomes of combination therapy in patients with chronic hepatitis C using artificial neural network. Hepat Mon. 2014 Jun 01;14(6):e17028. doi: 10.5812/hepatmon.17028. eCollection 2014 Jun. PMID: 24976838; PMCID: PMC4071357.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 49 entries